Arcus Biosciences Inc’s filing revealed that its Director KANEKO YASUNORI acquired Company’s shares for reported $0.2 million on Feb 27 ’25. In the deal valued at $10.06 per share,20,000 shares were bought. As a result of this transaction, KANEKO YASUNORI now holds 28,400 shares worth roughly $0.25 million.
Then, ROSEN TERRY J bought 19,800 shares, generating $201,465 in total proceeds. Upon buying the shares at $10.18, the Chief Executive Officer now owns 2,554,160 shares.
Before that, GILEAD SCIENCES, INC. bought 1,363,636 shares. Arcus Biosciences Inc shares valued at $14,999,996 were divested by the 10% Owner at a price of $11.00 per share. As a result of the transaction, GILEAD SCIENCES, INC. now holds 31,424,760 shares, worth roughly $273.71 million.
H.C. Wainwright upgraded its Arcus Biosciences Inc [RCUS] rating to a Buy from a a Neutral in a research note published on February 26, 2025; the price target was increased to $24 from $18. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late October with a ‘”a Neutral”‘ rating. Wells Fargo began covering RCUS with “an Overweight” recommendation on October 08, 2024. BofA Securities started covering the stock on November 18, 2022. It rated RCUS as “a Neutral”.
Price Performance Review of RCUS
On Monday, Arcus Biosciences Inc [NYSE:RCUS] saw its stock jump 1.75% to $8.71. Over the last five days, the stock has lost -1.02%. Arcus Biosciences Inc shares have fallen nearly -41.50% since the year began. Nevertheless, the stocks have fallen -50.37% over the past one year. While a 52-week high of $18.98 was reached on 01/07/25, a 52-week low of $6.50 was recorded on 04/07/25.
How much short interest is there in Arcus Biosciences Inc?
A steep rise in short interest was recorded in Arcus Biosciences Inc stocks on 2025-04-30, dropping by -0.54 million shares to a total of 7.91 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 8.45 million shares. There was a decline of -6.84%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 11, 2022 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $40 price target.
